Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald Radich

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2012
Adherence to BCR-ABL inhibitors: issues for CML therapyElias Jabbour, Giuseppe Saglio, Jerald Radich, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to PracticeKristen Pettit, Alexandra Rezazadeh, Ehab L Atallah, et al.
Current Hematologic Malignancy Reports|February 15, 2023
CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income CountriesMika Matsuzaki, Alicia Annamalay, Pat Garcia-Gonzalez, et al.
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic myelogenous leukemiaBrian J Druker, Stephen G O'Brien, Jorge Cortes, et al.
JCO Global Oncology|July 22, 2021
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid LeukemiaFisihatsion Tadesse, Getahun Asres, Abdulaziz Abubeker, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2025
Pharmacokinetic profile of novel reduced-dose Danziten<sup>™</sup> (nilotinib tablets) versus Tasigna<sup>®</sup> (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysisMichael Mauro, Jerald Radich, Paras Jain, et al.
JCO Clinical Cancer Informatics|July 7, 2025
Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in RemissionJ Felipe Montano-Campos, Erin Hahn, Eric Haupt, et al.
Blood|August 1, 2015
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosisMichael Deininger, Jerald Radich, Timothy C Burn, et al.
Research Square|January 16, 2026
A Framework for Locally Imputing and Predicting Biomarker Trajectories Under Irregular Monitoring: Application to Chronic Myeloid LeukemiaFelipe Montano-Campos, Patrick Heagerty, Eric Haupt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
Shared Identity and Patient Care: Adherence to Guideline-Recommended Biomarker Testing in Chronic Myeloid LeukemiaJ Felipe Montano-Campos, Erin E Hahn, Eric C Haupt, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2012
Adherence to BCR-ABL inhibitors: issues for CML therapyElias Jabbour, Giuseppe Saglio, Jerald Radich, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to PracticeKristen Pettit, Alexandra Rezazadeh, Ehab L Atallah, et al.
Current Hematologic Malignancy Reports|February 15, 2023
CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income CountriesMika Matsuzaki, Alicia Annamalay, Pat Garcia-Gonzalez, et al.
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic myelogenous leukemiaBrian J Druker, Stephen G O'Brien, Jorge Cortes, et al.
JCO Global Oncology|July 22, 2021
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid LeukemiaFisihatsion Tadesse, Getahun Asres, Abdulaziz Abubeker, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2025
Pharmacokinetic profile of novel reduced-dose Danziten<sup>™</sup> (nilotinib tablets) versus Tasigna<sup>®</sup> (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysisMichael Mauro, Jerald Radich, Paras Jain, et al.
JCO Clinical Cancer Informatics|July 7, 2025
Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in RemissionJ Felipe Montano-Campos, Erin Hahn, Eric Haupt, et al.
Blood|August 1, 2015
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosisMichael Deininger, Jerald Radich, Timothy C Burn, et al.
Research Square|January 16, 2026
A Framework for Locally Imputing and Predicting Biomarker Trajectories Under Irregular Monitoring: Application to Chronic Myeloid LeukemiaFelipe Montano-Campos, Patrick Heagerty, Eric Haupt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
Shared Identity and Patient Care: Adherence to Guideline-Recommended Biomarker Testing in Chronic Myeloid LeukemiaJ Felipe Montano-Campos, Erin E Hahn, Eric C Haupt, et al.
Pageof 10